Search Results - "English, Patricia A"

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma by English, Patricia A, Williams, J Andrew, Martini, Jean-François, Motzer, Robert J, Valota, Olga, Buller, Richard E

“…Assess patient-level utility of suggested pretreatment biomarkers of sunitinib in advanced renal cell carcinoma. Kaplan-Meier analysis of data from a…”
Get full text

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014 by Messersmith, Wells A, Shapiro, Geoffrey I, Cleary, James M, Jimeno, Antonio, Dasari, Arvind, Huang, Bo, Shaik, M Naveed, Cesari, Rossano, Zheng, Xianxian, Reynolds, Jennifer M, English, Patricia A, McLachlan, Karen R, Kern, Kenneth A, LoRusso, Patricia M

“…To estimate the maximum tolerated dose (MTD) for continuous oral administration of the γ-secretase inhibitor PF-03084014, determine the recommended phase II…”
Get full text

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma by Motzer, Robert J., Hutson, Thomas E., Hudes, Gary R., Figlin, Robert A., Martini, Jean-Francois, English, Patricia A., Huang, Xin, Valota, Olga, Williams, J. Andrew

“…Purpose Sunitinib is a first-line advanced renal cell carcinoma (RCC) standard of care. In a randomized phase II trial comparing sunitinib treatment schedules,…”
Get full text

Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma by Escudier, Bernard, Rini, Brian I, Motzer, Robert J, Tarazi, Jamal, Kim, Sinil, Huang, Xin, Rosbrook, Brad, English, Patricia A, Loomis, A. Katrina, Williams, J. Andrew

“…Micro-Abstract Clinical outcomes among patients who receive antiangiogenic therapies vary; identification of genetic biomarkers can guide treatment of…”
Get full text

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours by Schöffski, Patrick, Jones, Suzanne F, Dumez, Herlinde, Infante, Jeffrey R, Van Mieghem, Elke, Fowst, Camilla, Gerletti, Paola, Xu, Huiping, Jakubczak, John L, English, Patricia A, Pierce, Kristen J, Burris, Howard A

“…Abstract This phase I study (ClinicalTrials.gov ID: NCT00424632 ) evaluated the safe dose, pharmacokinetics, and pharmacodynamics of the aurora kinase A and B…”
Get full text

Effectiveness of a geriatric evaluation unit. A randomized clinical trial by Rubenstein, L Z, Josephson, K R, Wieland, G D, English, P A, Sayre, J A, Kane, R L

“…We randomly assigned frail elderly inpatients with a high probability of nursing-home placement to an innovative geriatric evaluation unit intended to provide…”
Get more information

Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA) by Turner, Nicholas C., Jiang, Yuqiu, O'Leary, Ben, Hrebien, Sarah, Cristofanilli, Massimo, Andre, Fabrice, Loibl, Sibylle, English, Patricia A., Zhang, Ke, Randolph, Sophia, Bartlett, Cynthia Huang, Koehler, Maria, Loi, Sherene

“…Abstract only…”
Get full text

Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients by Escudier, Bernard J., Rini, Brian I., Martini, Jean-Francois, Chang, Wayne Yen-Hwa, Breza, Jan, Magheli, Ahmed, Svedman, Christer, Lopatin, Margarita, Knezevic, Dejan, Goddard, Audrey D., English, Patricia A, Li, Rachel, Lin, Xun, Valota, Olga, Cartenì, Giacomo, Staehler, Michael D., Motzer, Robert J., Ravaud, Alain

“…Abstract only 4508 Background: Adjuvant therapy with sunitinib (SU) compared with placebo (PBO) prolonged disease-free survival (DFS) in 615 patients (pts)…”
Get full text

Genotype correlations with blood pressure and efficacy outcomes from the randomized phase III AXIS trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma by Escudier, Bernard J., Rini, Brian I., Motzer, Robert J., Tarazi, Jamal Christo, Kim, Sinil, Huang, Xin, Rosbrook, Brad, English, Patricia A, Loomis, A Katrina, Williams, James Andrew

“…Abstract only…”
Get full text

Identification of tumor biomarkers for sunitinib in advanced renal cell carcinoma (RCC) by Dai, Hongyue, Fishman, Mayer N., Ching, Keith A., Williams, James Andrew, Teer, Jamie K., English, Patricia A., Zhang, Yonghong, Murray, Brion W., Kumar, Naveen, Huntsman, Shane, Berglund, Anders E., Dalton, William S., Matczak, Ewa, Martini, Jean-Francois

“…Abstract only 470 Background: Sunitinib is a standard of care for advanced RCC. Despite efforts to identify predictive molecular markers for patient selection,…”
Get full text

Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control by Simonelli, Matteo, Denlinger, Crystal Shereen, Goff, Laura Williams, Noberasco, Cristina, Kim, Tae-You, Thomas, Melanie B., De Braud, Filippo G., Zucali, Paolo A., Santoro, Armando, English, Patricia A, Gallo-Stampino, Corrado, Wang, Erjian, Carpentieri, Marina, Williams, James Andrew

“…Abstract only…”
Get full text

Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis by Goff, Laura Williams, Borghaei, Hossein, Cohen, Roger B., Berlin, Jordan, Noberasco, Cristina, Stampino, Corrado Gallo, Wang, Erjian, Williams, James Andrew, English, Patricia A, De Braud, Filippo

“…Abstract only e13606 Background: The proangiogenic activity of Transforming Growth Factor β (TGF-β) on vasculature is exerted by selectively binding to its…”
Get full text

The relationship between T-cell levels and CMV infection in asymptomatic HIV-1 antibody-positive homosexual men by Leach, C T, Cherry, J D, English, P A, Hennessey, K, Giorgi, J V, Visscher, B R, Dudley, J P, Detels, R

“…To investigate the relationship between cytomegalovirus (CMV) infection and progression of HIV-1 disease, a group of 234 asymptomatic, HIV-1 antibody-positive…”
Get more information

Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial by Audet, Marie-Lise, Allo, Ghassan, Weng, Xiaoduan, Kim, Lucia, Gologan, Olguta, Kamel-Reid, Suzanne, Siu, Lillian, Coutlee, Francois, Laurie, Scott Andrew, Hotte, Sebastien J., Singh, Simron, Winquist, Eric, Chia, Stephen K. L., Chen, Eric Xueyu, Chan, Kelvin K., English, Patricia A, Taylor, Ian, Quinn, Susan, Mormont, Christine, Soulieres, Denis

“…Abstract only 6041 Background: Dacomitinib is an irreversible pan-HER TKI with preclinical (EGFRvIII+ cell lines, SCCHN xenografts) and clinical activity…”
Get full text

Predictors of clinical AIDS in young homosexual men in a high-risk area by Detels, R, Visscher, B R, Fahey, J L, Sever, J L, Gravell, M, Madden, D L, Schwartz, K, Dudley, J P, English, P A, Powers, H

“…One hundred and sixty-seven homosexual men in Los Angeles characterized by HIV antibody, T-cell numbers, titres to cytomegalovirus (CMV), and specific sexual…”
Get more information

Patterns of CD4+ cell changes after HIV-1 infection indicate the existence of a codeterminant of AIDS by Detels, R, English, P A, Giorgi, J V, Visscher, B R, Fahey, J L, Taylor, J M, Dudley, J P, Nishanian, P, Muñoz, A, Phair, J P

“…Successive interval slopes of CD4+ cells each constructed from levels at three consecutive 6 month visits were compared over 3 years of follow-up among 565…”
Get more information